CX3CR1 Protein
Overview
CX3CR1 (C-X3-C Motif Chemokine Receptor 1), also known as the fractalkine receptor or CX3C chemokine receptor 1, is a G protein-coupled receptor (GPCR) expressed primarily on monocytes, macrophages, dendritic cells, and [microglia](/cell-types/microglia-neuroinflammation). It binds the membrane-bound and soluble forms of fractalkine (CX3CL1), mediating neuroprotective and neurotoxic signaling depending on context.
...CX3CR1 Protein
Overview
CX3CR1 (C-X3-C Motif Chemokine Receptor 1), also known as the fractalkine receptor or CX3C chemokine receptor 1, is a G protein-coupled receptor (GPCR) expressed primarily on monocytes, macrophages, dendritic cells, and [microglia](/cell-types/microglia-neuroinflammation). It binds the membrane-bound and soluble forms of fractalkine (CX3CL1), mediating neuroprotective and neurotoxic signaling depending on context.
<div class="infobox">
<table>
<tr><th>Protein Name</th><td>CX3CR1 (Fractalkine Receptor)</td></tr>
<tr><th>Gene Symbol</th><td>CX3CR1</td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/P41597">P41597</a></td></tr>
<tr><th>Protein Class</th><td>G protein-coupled receptor (GPCR), Chemokine Receptor</td></tr>
<tr><th>Molecular Weight</th><td>~40.5 kDa</td></tr>
<tr><th>Structure</th><td>7 transmembrane domains</td></tr>
<tr><th>Subcellular Localization</th><td>Plasma membrane, endosomes</td></tr>
<tr><th>Expression</th><td>Monocytes, macrophages, dendritic cells, microglia, some [neurons](/entities/neurons)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer-disease" style="color:#ef9a9a">ALZHEIMER DISEASE</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-ba3a948a" style="color:#ce93d8" title="Score: 0.46">Fractalkine Axis Amplification via CX3CR...</a><br><a href="/hypothesis/h-782b40b1" style="color:#ce93d8" title="Score: 0.38">Optogenetic Microglial Deactivation via ...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">660 edges</a></td>
</tr>
</table>
</div>
Structure
CX3CR1 is a class A GPCR with seven transmembrane α-helices connected by three extracellular and three intracellular loops. The N-terminus contains multiple glycosylation sites important for ligand binding. The receptor possesses a DRY motif at the boundary of the third transmembrane domain and intracellular loop 2, essential for G protein coupling.
Normal Function
Fractalkine Signaling
CX3CR1 binds fractalkine (CX3CL1), a unique membrane-bound chemokine that can be shed to form a soluble chemoattractant. This receptor-ligand pair operates in both membrane-bound and soluble modes:
- Membrane-bound fractalkine: Functions as an adhesion molecule, mediating cell-cell contact between CX3CR1-expressing cells and neurons/expressing membrane fractalkine
- Soluble fractalkine: Acts as a chemoattractant, recruiting CX3CR1+ immune cells to sites of injury
Immune Cell Regulation
CX3CR1 plays critical roles in:
- Monocyte recruitment and migration to inflamed tissues
- Microglial surveillance and response to injury
- Dendritic cell trafficking and antigen presentation
- Polarization of macrophages toward anti-inflammatory (M2) phenotype
Role in Neurodegeneration
Alzheimer's Disease
In Alzheimer's disease, CX3CR1 signaling has complex, context-dependent effects:
Microglial Activation: CX3CR1 regulates microglial activation state. Loss of CX3CR1 leads to enhanced pro-inflammatory cytokine production and worsened amyloid pathology in mouse models.
Amyloid Clearance: CX3CR1-expressing microglia can phagocytose amyloid-β plaques. Fractalkine signaling enhances this clearance capacity.
Synaptic Pruning: During development, CX3CR1 regulates synaptic pruning. Dysregulation may contribute to synapse loss in AD.
Neurotoxicity: Soluble fractalkine can be neuroprotective, but chronic elevation may contribute to excitotoxicity through [NMDA receptor](/entities/nmda-receptor) modulation.Key References:
- [Bachstetter et al., 2013 - Fractalkine receptor deficiency (CX3CR1) in AD](https://doi.org/10.1016/j.neurobiolaging.2012.05.011)
- [Cardona et al., 2006 - CX3CR1 deficiency in AD mouse models](https://doi.org/10.1038/nm1239)
- [Lauro et al., 2015 - CX3CL1/CX3CR1 in synaptic dysfunction](https://doi.org/10.1007/s12017-015-8357-7)
Parkinson's Disease
CX3CR1 signaling in PD is primarily studied in the context of microglial activation and neuroinflammation:
Neuroinflammation: CX3CR1 regulates microglial production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Elevated fractalkine may exacerbate neuroinflammation.
Dopaminergic Neuron Survival: Fractalkine has neurotrophic effects on dopaminergic neurons. The CX3CR1 pathway may protect against 6-OHDA and MPTP toxicity.
[Blood-Brain Barrier](/entities/blood-brain-barrier): CX3CR1 on peripheral monocytes may influence BBB permeability in PD.Key References:
- [Shan et al., 2018 - CX3CR1 in 6-OHDA model](https://doi.org/10.1016/j.neuropharm.2018.01.034)
- [Matsumoto et al., 2017 - Fractalkine and PD](https://doi.org/10.1016/j.neurobiolaging.2017.05.019)
- [Pabon et al., 2011 - CX3CR1 in MPTP model](https://doi.org/10.1016/j.neuropharm.2011.02.011)
Amyotrophic Lateral Sclerosis (ALS)
In ALS, CX3CR1 may play dual roles:
Microglial Modulation: CX3CR1 deficiency accelerates disease progression in SOD1 mouse models, suggesting a protective role.
Motor Neuron Protection: Fractalkine signaling may protect motor neurons from excitotoxicity.Key References:
- [Zhang et al., 2019 - CX3CR1 in ALS models](https://doi.org/10.1016/j.neurobiolaging.2019.06.003)
- [Ferrara et al., 2017 - Fractalkine in ALS](https://doi.org/10.1016/j.expneurol.2017.02.012)
Huntington's Disease
CX3CR1 signaling in HD is less characterized but appears to modulate microglial activation:
Neuroinflammation: Altered CX3CR1 expression may contribute to chronic neuroinflammation in HD.
Striatal Vulnerability: The striatum shows high fractalkine expression, potentially relevant to HD pathology.Therapeutic Targeting
CX3CR1 modulators are being investigated for neurodegenerative diseases:
| Approach | Mechanism | Development Stage | Notes |
|----------|-----------|-------------------|-------|
| CX3CR1 Agonists | Enhance fractalkine signaling | Preclinical | May improve microglial clearance |
| CX3CR1 Antagonists | Block pro-inflammatory signaling | Preclinical | Risk of impairing beneficial functions |
| CX3CL1/Fractalkine | Recombinant protein | Preclinical | Delivery challenges |
| Small Molecule Modulators | Direct receptor modulation | Early discovery | Limited by GPCR druggability |
Challenges
Dual Nature: The receptor has both protective (phagocytosis) and harmful (inflammation) effects
BBB Penetration: Therapeutic delivery to CNS is challenging
Cell Type Specificity: Effects differ between microglia and peripheral monocytesKey References:
- [Lauro et al., 2020 - CX3CR1 as therapeutic target](https://doi.org/10.1016/j.pharmthera.2020.107583)
- [Hammond et al., 2019 - Microglial heterogeneity and CX3CR1](https://doi.org/10.1016/j.tics.2019.05.003)
Gene-Environment Interactions
CX3CR1 polymorphisms have been studied in neurodegeneration:
- CX3CR1 V249I: Associated with altered AD risk in some populations
- CX3CR1 T280M: May influence microglial response and PD progression
Cross-Links
- [CX3CR1 Gene](/genes/cx3cr1)
- [Fractalkine (CX3CL1)](/proteins/fractalkine)
- [Microglia](/cell-types/microglia)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
Pathway & Interaction Diagram
Interactive diagram showing CX3CR1 key relationships in the SciDEX knowledge graph (15 connections shown).
Mermaid diagram (expand to render)
See Also
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Bachstetter et al., Fractalkine receptor deficiency in Alzheimer's disease (2013) (2013)](https://doi.org/10.1016/j.neurobiolaging.2012.05.011)
[Cardona et al., CX3CR1 deficiency in models of neuroinflammation (2006) (2006)](https://doi.org/10.1038/nm1239)
[Lauro et al., CX3CL1/CX3CR1 axis in synaptic dysfunction (2015) (2015)](https://doi.org/10.1007/s12017-015-8357-7)
[Shan et al., CX3CR1 in Parkinson's disease models (2018) (2018)](https://doi.org/10.1016/j.neuropharm.2018.01.034)
[Matsumoto et al., Fractalkine and neurodegeneration (2017) (2017)](https://doi.org/10.1016/j.neurobiolaging.2017.05.019)
[Pabon et al., CX3CR1 deficiency in MPTP model (2011) (2011)](https://doi.org/10.1016/j.neuropharm.2011.02.011)
[Zhang et al., CX3CR1 in ALS (2019) (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.003)
[Ferrara et al., Fractalkine in ALS (2017) (2017)](https://doi.org/10.1016/j.expneurol.2017.02.012)
[Lauro et al., CX3CR1 as therapeutic target (2020) (2020)](https://doi.org/10.1016/j.pharmthera.2020.107583)
[Hammond et al., Microglial heterogeneity (2019) (2019)](https://doi.org/10.1016/j.tics.2019.05.003)